[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Delaware\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":496},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,47,74,96,118,139,164,188,212,236,260,283,309,336,360,381,409,434,455,473],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100573375","phase-4-disentangling-the-effects-of-daily-stress-sleep-and-sex-hormones-on-accelerated-vascular-aging-in-midlife-women-100573375",false,"NCT06745466","Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women","V-RISES","Inclusion Criteria:\n\n* Female\n* Age 40-55\n* Premenopausal\n\nExclusion Criteria:\n\n* Pregnancy (including a positive urine pregnancy test), planning to become pregnant, or breast-feeding\n* Peri- or post-menopausal\n* Unstable or diagnosed chronic clinical disease, including cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological disease\n* Current or lifetime major psychiatric illness (e.g., major depressive disorder, bipolar disorder, schizophrenia, eating disorders)\n* History of hysterectomy (complete or partial), polycystic ovary syndrome, endometrial hyperplasia, irregular menstrual cycles, or endometrial ablation\n* Suspected potential presence of obstructive sleep apnea (STOP-Bang score \\>3) or insomnia (Insomnia Severity Index score \\>15)\n* Current or recent (within 8 wks) use of medications that could conceivably alter cardiovascular function or sleep health\n* Changes or alterations in medication status (starting a new, additional, or different medication or changing the dose of a current medication)\n* Body mass index \\>35 kg\u002Fm2\n* Tobacco or nicotine use, including vaping and electronic cigarettes\n* Working night-time or rotating shift work within the previous 3 months\n* Trans-meridian travel during study enrollment (inclusive of the entire duration of enrollment and the period between testing cycles)\n* Known allergies to pharmacological agents\u002Fdrugs\n* Current use of long-acting reversible contraception (LARC; e.g., IUDs, birth control implants)\n* Known latex allergy",true,"FEMALE","40 Years","55 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The purpose of this study is to identify the impact of estradiol (E2) on the associations between (a) responsivity to daily stress or (b) sleep variability with vascular function in midlife premenopausal women.",[28,29],"Estrogen","Premenopause",[29,28,31,32,33],"Stress","Sleep","Vascular function","RECRUITING","2026-07-01",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2024-11-15",{"date":42,"type":22},"2027-10",{"name":44,"class":45},"University of Delaware","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100508520","category-learning-retention-in-adults-with-and-without-developmental-language-disorder-100508520","NCT05901493","Category Learning Retention in Adults With and Without Developmental Language Disorder","Improving the Retention of Speech-Perceptual Learning in Adults With and Without Language Disorder","Time2Learn","Inclusion Criteria:\n\n* native speakers of American English\n* Grew up in a household in which only American English was spoken\n* 18-55 years of age\n* Typical vision \\& hearing\n* (Aim 2) access to headphones\u002Fdevices capable of accessing experiment script via internet\n* Must meet criteria for Group membership as either TD or DLD\n\nExclusion Criteria:\n\n* History of neurological disorders\n* History of psychiatric disorders\n* History of socio-emotional disorders\n* On prescription medication(s) that alter sleep","ALL","18 Years",{"count":58,"type":22},540,[60],"NA","Approximately 7% of the population experiences developmental language disorder (DLD), a language disorder with unclear causes. DLD affects communication beyond adolescence and poses challenges for education and career advancement due to difficulties in learning and memory. Recent research suggests that adults with DLD struggle with overnight memory consolidation, indicating a need for effective learning and memory support. This project aims to determine the optimal training schedule for perceptual memory retention in adults with and without DLD. The study involves recruiting 240 adults (120 with DLD, 120 without) for speech-perceptual training with different training schedules. The researchers predict that the manipulation of training schedules will interact with circadian preference and overnight consolidation, leading to the discovery of the best practice schedule for speech sound retention. Additionally, 300 more adults (150 with DLD, 150 without) will be recruited to investigate how optimal training schedules interact with reflexive and reflective learning strategies. The time course of learning and retention will be tracked during reflexive and reflective categorization training in six different training schedules.",[63,64],"Developmental Language Disorder","Adults Without Language Disorder","2026-05-26",{"date":67,"type":38},"2026-05-29",{"date":69,"type":38},"2022-10-23",{"date":71,"type":22},"2027-07-31",{"name":44,"class":45},2,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":46},"100341474","exercise-and-motor-learning-after-stroke-study-3-100341474","NCT03726047","Exercise and Motor Learning After Stroke (Study #3)","Feedback and Cognition During Locomotor Learning Post Stroke","Inclusion Criteria:\n\nAge 18-85 Single, unilateral, chronic stroke (\\>6 months post-stroke), confirmed by MRI or CT scan Score \\>1 on question 1b and \\>0 on question 1c of the NIH Stroke Scale Able to walk at self-selected speed without assistance from another person Resting heart rate between 40-100 beats per minute Resting blood pressure between 90\u002F60 to 185\u002F100\n\nExclusion Criteria:\n\nEvidence of cerebellar stroke on clinical MRI or CT scan, because of role of cerebellum in learning Other neurologic conditions in addition to stroke Inability to walk outside the home prior to the stroke Coronary artery bypass graft or myocardial infarction within past 3 months, Musculoskeletal pain that limits walking Inability to communicate with investigators Visual field cut Neglect Unexplained dizziness in last 6 months","85 Years",{"count":83,"type":22},80,[60],"Subjects with chronic stroke (\\> 6 months post-stroke) will learn a new walking pattern through distorted visual feedback. Retention of the pattern will be tested without visual feedback immediately after learning and 24 hours later. Subjects will be randomly assigned to the control group or the exercise group. The control group will simply complete the learning task. The exercise group will complete 5 minutes of exercise immediately following the first retention test to test for the effects of exercise on retention 24 hours later.",[87],"Stroke","2026-05-19",{"date":90,"type":38},"2026-05-20",{"date":92,"type":38},"2019-12-01",{"date":94,"type":22},"2027-02",{"name":44,"class":45},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100625252","phase-4-menopausal-hormones-and-sympathetic-activation-100625252","NCT07420218","Menopausal Hormones and Sympathetic Activation","Impact of FSH and Estradiol on Sympathetic Function in Menopausal Women","Inclusion Criteria:\n\n* Perimenopausal (based on changes in menstrual cycle)\n* Ages 40-58 years\n\nExclusion Criteria:\n\n* History of CVD, blood clots, stroke\n* History of Cancer\n* History of Liver or Kidney disease\n* History of Neurological disease\n* Diabetes\n* BMI\\>35kg\u002Fm2\n* Pregnant, planning on becoming pregnant, or breast feeding\n* Allergy to Latex\n* Use of Tobacco\n* Hysterectomy\n* Blood pressure \\>140\u002F90 mmHg\n* Current or prior use of hormone replacement therapy (within 3 mo)","58 Years",{"count":83,"type":22},[25],"The purpose of this study is to understand how changes in menopausal hormones like estradiol and follicle-stimulating hormone (FSH) impact sympathetic nervous system function. To do so, the investigators will use a medication to control the production of estradiol and FSH, and in some participants, add-back estradiol to isolate its effects. The investigators will measure sympathetic activation centrally (in the brain using MRI), peripherally in the nervous system, and also examine adrenergic receptor mediated control of vascular function.",[108],"Perimenopausal Women","NOT_YET_RECRUITING","2026-03-25",{"date":112,"type":38},"2026-03-27",{"date":114,"type":22},"2026-09-01",{"date":116,"type":22},"2030-12-31",{"name":44,"class":45},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":16,"sex":55,"minAge":18,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":46},"100523371","phase-4-forebrain-electroneutral-transporters-in-salt-sensitive-hypertension-an-mri-study-100523371","NCT06094816","Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study","Inclusion Criteria:\n\n* Age: \\> 40 years or \\\u003C 60 years\n* Blood pressure: \\> 100\u002F60 mmHg or \\\u003C 140\u002F90 mmHg\n* BMI: \\> 18.5 kg\u002Fm2 or \\\u003C 35 kg\u002Fm2\n* Serum potassium: \\> 3.5 mmol\u002FL or \\\u003C 5.5 mmol\u002FL\n* No history of cardiovascular, renal, metabolic, or neurological disease\n\nExclusion Criteria:\n\n* Age: \\\u003C 40 years or \\> 60 years\n* Blood pressure: \\\u003C 100\u002F60 mmHg or \\> 140\u002F90 mmHg\n* BMI: \\\u003C 18.5 kg\u002Fm2 or \\> 30 kg\u002Fm2\n* Serum potassium: \\\u003C 3.5 mmol\u002FL or \\> 5.5 mmol\u002FL\n* Abnormal ECG\n* History of - cardiovascular, cancer, metabolic, respiratory, renal disease\n* Hormone replacement therapy\n* Current tobacco or nicotine use\n* Pregnant or nursing mothers\n* Major brain injury (concussions do not count)\n* Clinically diagnosed psychiatric or neurological disorder\n* Clinically diagnosed anxiety or depression\n* Psychiatric, neurological, anxiety or depression medications\n* Hypertension medications\n* Sulfonamide drug allergy\n* Contra-indications to MRI (implants, metal, etc)\n* Claustrophobia","60 Years",{"count":126,"type":22},120,[25],"The overall objective of this project is to identify the key salt-sensing regions of the brain and determine the underlying mechanism of sodium sensing. The investigators will assess how the brain responds to an acute increase of salt in the blood using MRI. This will be done during a 30-minute infusion of a saline solution containing 3% salt. One trial will be conducted with a salt sensing channel blocker and one trial without the salt sensing channel blocker. This will help to assess the role of a specific salt sensing channel in the brain. Salt sensitivity of BP will be assessed using 7-day dietary feeding where participants will be given food to consume for 7-days. Comparisons will be made between salt resistant (no change in blood pressure going from low to high salt diets) and salt sensitive adults (a change in blood pressure going from low to high salt diets). The investigators think the changes in MRI will be greater in salt sensitive compared to salt resistant subjects.",[130],"Salt-Sensitivity of Blood Pressure","2026-03-20",{"date":133,"type":38},"2026-03-24",{"date":135,"type":38},"2024-03-05",{"date":137,"type":22},"2028-07-01",{"name":44,"class":45},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":16,"sex":55,"minAge":56,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":46},"100370272","mechanisms-underlying-the-protective-vascular-effects-of-dietary-potassium-in-humans-100370272","NCT04101188","Mechanisms Underlying the Protective Vascular Effects of Dietary Potassium in Humans","Inclusion Criteria:\n\n* healthy\n* normal blood pressure\n* normal resting ECG\n\nExclusion Criteria:\n\n* hypertension\n* history of heart disease\n* diabetes\n* kidney disease\n* obese (BMI ≥30)\n* significant weight changes in the last 6 months\n* use of tobacco products\n* pregnant\n* on a special diet (gluten free; vegan)\n* take any medications for the above conditions\n* endurance trained athletes","45 Years",{"count":147,"type":22},90,[60],"Americans continue to consume high amounts of sodium. Potassium is notable for its blood pressure lowering effects but less is known regarding its effect on the vasculature. This investigation seeks to determine the role of dietary potassium on the vasculature in the presence of a high sodium diet in salt-resistant adults.",[151],"Cardiovascular Risk Factor",[153,154,155],"Dietary Potassium","Dietary Sodium","Vascular Health","2026-03-02",{"date":158,"type":38},"2026-03-04",{"date":160,"type":38},"2020-01-16",{"date":162,"type":22},"2026-07-31",{"name":44,"class":45},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":46},"100627552","nested-pilot-study-comparing-two-treatments-to-reduce-type-2-diabetes-risk-in-at-risk-delawareans-100627552","NCT07450118","Nested Pilot Study Comparing Two Treatments to Reduce Type 2 Diabetes Risk in At-Risk Delawareans","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Prediabetes confirmed by blood test result within 12 months of enrollment, previous diagnosis of gestational diabetes mellitus (GDM), or positive screening for prediabetes based on the Prediabetes Risk Test\n* BMI of 25 kg\u002Fm² or greater (23 kg\u002Fm² or greater for Asian Americans)\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* BMI less than 25 kg\u002Fm² (less than 23 kg\u002Fm² for Asian Americans)\n* No current diagnosis of prediabetes or gestational diabetes mellitus\n* Prior diagnosis of type 1 or type 2 diabetes\n* Pregnancy at the time of enrollment\n* Development of a medical condition that, in the PI's judgment, could be exacerbated by the study interventions (e.g., eating disorder, severe sleep disorder)",{"count":171,"type":22},40,[60],"This nested pilot Randomized Clinical Trial will determine whether the Diabetes Prevention Program (DPP) enhanced with evidence-based sleep health and time restricted eating interventions (\"DPP++\") is more effective than the DPP alone for improving metabolic and cardiovascular metrics in 40 overweight\u002Fobese adults with prediabetes.",[175],"Prediabetes",[175,177,178,179,180],"Time Restricted Eating","Sleep Health","Cardiometabolic Health","Circadian Health","2026-02-26",{"date":158,"type":38},{"date":184,"type":22},"2026-05",{"date":186,"type":22},"2027-06",{"name":44,"class":45},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":55,"minAge":19,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":46},"100597157","pain-and-split-belt-motor-learning-in-older-adults-100597157","NCT07054840","Pain and Split-belt Motor Learning in Older Adults","Inclusion Criteria:\n\n* Age 55-90 years old\n* Self-identifying as generally medically healthy\n* Able to read, write and speak English\n* Able to provide informed consent and attend all testing sessions\n* Willing to undergo the experimental pain paradigm, if selected\n\nExclusion Criteria:\n\n* Resting heart rate \\\u003C 50 or \\> 100 bpm\n* Resting blood pressure \\\u003C 90\u002F60 or \\> 165\u002F95\n* Any history or current mental health condition, learning\u002Fdevelopmental disability or cognitive impairment, including severe untreated ADD\u002FADHD, severe untreated anxiety, severe untreated depression, autism spectrum disorder, insomnia, mild cognitive impairment, etc. (Mild to moderate treated ADD\u002FADHD, anxiety, and\u002For depression are allowed.)\n* Score on the Montreal Cognitive Assessment (MoCA) \\\u003C23\n* Score on the Generalized Anxiety Disorder-7 Scale ≥ 10\n* Score on the Patient Health Questionnaire-2 ≥ 2 and score on the Patient Health Questionnaire-9 ≥ 10\n* Any current (within last 3 month) or chronic medical conditions, including any musculoskeletal, cardiovascular, pulmonary, metabolic, psychiatric or neurological diagnosis that affects activities of daily living or would confound testing or place the subject at risk by participating, such as a significant cardiovascular condition or event (e.g., heart attack \\\u003C 3 months ago, uncontrolled atrial fibrillation, uncontrolled angina, congestive heart failure, chronic obstructive pulmonary disorder, or peripheral vascular disease)\n* Any impaired sensation or weakness in either lower extremity\n* History of serious concussion or head injury, defined as a loss of consciousness for \\> 5 minutes and\u002For requiring medical treatment, or \\> 2 concussions over the lifespan\n* Any history of acute or chronic problems with balance, any dizziness, or \\> 1 fall in the last 12 months\n* Currently or regularly using any analgesic medications, over-the-counter remedies, or any other treatment for the purposes of pain relief (i.e., baby aspirin for heart health is allowed)\n* Any current or chronic pain condition during the last year, located anywhere in the body with an intensity of \\> 2\u002F10\n* Allergy to capsaicin or hot peppers\n* Any skin lesion, breakage or irritation in the area targeted for the painful stimulus\n* Significant skin sensitivity to soaps\u002Fcreams\u002Fperfumes or to heat\n* Poor circulation in the area targeted for the painful stimulus\n* Prior participation in a split-belt locomotor learning study in the Neuromotor Behavior Lab in the past 2 years","90 Years",{"count":196,"type":22},34,[60],"The purpose of this research is to investigate the impact of acute pain, induced using an experimental pain paradigm of capsaicin paired with heat, on implicit locomotor learning and its retention in older adults.",[200,201,202,203],"Aging","Older Adults","Pain","Motor Learning","2025-12-03",{"date":206,"type":38},"2025-12-04",{"date":208,"type":38},"2025-08-26",{"date":210,"type":22},"2026-05-31",{"name":44,"class":45},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":16,"sex":55,"minAge":145,"maxAge":194,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":46},"100554002","online-interplay-between-deciding-and-acting-with-mild-cognitive-impairment-100554002","NCT06493422","Online Interplay Between Deciding and Acting With Mild Cognitive Impairment","Inclusion Criteria:\n\n1. age 45 - 90 years\n2. Perfect or corrected vision\n3. Ability to reach\n4. Neurotypical Age-Matched control participants - No history of neurological disorders or injury.\n5. Mild Cognitive Impairment participants - clinical diagnosis of amnestic mild cognitive impairment.\n\nExclusion Criteria:\n\n1. Any injury or condition that impacts reaching\n2. Traumatic brain injury, such as concussion, in the last 6 months.\n3. Neurotypical Age-Matched control participants: Modified Telephone Interview for Cognitive Status (TICS-m) score \\\u003C 34\n4. Mild Cognitive Impairment participants: Modified Telephone Interview for Cognitive Status (TICS-m) score \\> 34\n5. Mild Cognitive Impairment participants: Mini-Mental State Examination Second Edition (MMSE-2) score \\\u003C 21.",{"count":219,"type":22},60,[60],"The investigators aim to understand the interplay and neural structures involved with decision--making and movement for participants with mild cognitive impairment. Rapidly deciding and acting becomes bottlenecked with mild cognitive impairment and Alzheimer's, leading to detrimental outcomes such as falling and car crashes. The investigators work will have a tangible impact by discovering sensitive biomarkers to detect disease onset and pave the way for informed and effective neurorehabilitation.",[223],"Mild Cognitive Impairment",[225,226,227],"Reaching","Brain","Decisions","2025-10-10",{"date":230,"type":38},"2025-10-15",{"date":232,"type":38},"2025-01-28",{"date":234,"type":22},"2026-06-30",{"name":44,"class":45},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":16,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":46},"100582239","linking-affective-dynamics-in-response-to-daily-stress-to-peripheral-vascular-function-in-working-age-adults-100582239","NCT06860724","Linking Affective Dynamics in Response to Daily Stress to Peripheral Vascular Function in Working Age Adults","Inclusion Criteria:\n\n* Males and females aged 18-55 yrs\n* Non-depressed health adults (HA) will have no evidence of current or lifetime history of major psychiatric illness, assessed by the MINI and self-report and confirmed by a Licensed Clinical Psychologist\n* Adults with major depressive disorder (MDD) must meet the DSM-5 criteria for MDD and be currently symptomatic, assessed by the MINI and confirmed by a Licensed Clinical Psychologist; participants with co-morbid anxiety, stress, and trauma-related disorders will be included\n* Absence of unstable or chronic clinical disease, including cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological disease, as determined by medical history, physical examination, blood chemistries, and 12-lead resting electrocardiogram; however, to ensure a more generalizable sample, adults with elevated systolic BP (\\\u003C130mmHg), direct low-density lipoprotein (\\\u003C160mg\u002Fdl), and glucose (HbA1c \\\u003C5.7%) will be included\n* Participants must have a level of understanding of the English language sufficient to provide informed consent and to agree to all tests and procedures, as well as the capacity and willingness to attend all study related visits and to comply with the study protocol\n\nExclusion Criteria:\n\nSubjects will be excluded at the discretion of the PI\u002Fcollaborating clinicians or for any of the following reasons:\n\n* \\\u003C18 or \\>55 yrs\n* Lifetime or current co-morbid neuropsychiatric disease (bipolar disorder, psychotic disorders, schizophrenia, eating disorders, obsessive-compulsive disorder, alcohol or substance use disorders)\n* Serious and imminent active suicidal\u002Fhomicidal ideation with intent, plans, or behaviors, determined by the Licensed Clinical Psychologist or other clinical study team staff\n* Diagnosed chronic clinical disease, including cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological disease, as determined by medical history, physical examination (resting systolic BP ≥130mmHg, body mass index ≥35 kg\u002Fm2), clinically significant abnormal blood chemistries (direct low-density lipoprotein ≥160mg\u002Fdl, HbA1c≥5.7%), and clinically significant abnormal 12-lead resting ECG\n* Current or recent use (within last 8 wks) of medications that alter cardiovascular function or psychoactive or psychopharmacological drugs \\[including (but not limited to) antidepressants, antipsychotics, benzodiazepines, mood stabilizers, sedatives\u002Fhypnotics, dopaminergic agents, stimulants, buspirone, and triptans\\]\n* Tobacco use (including electronic cigarettes)\n* Females who are pregnant, breastfeeding, or planning to become pregnant; female subjects of child-bearing age must have a negative urine pregnancy test on the day of all experimental visits\n* Current or past use of hormone replacement therapy\n* Allergy to study drugs or pharmacological agents",{"count":243,"type":22},18,[60],"The objective of this proposal is to determine whether heightened negative affective responsivity (NA-R) to daily stressors is related to blunted nitric oxide (NO)-mediated endothelium-dependent dilation (EDD) in working age adults and the extent to which this association is impacted by major depressive disorder (MDD).",[247],"Major Depressive Disorder",[249,250,251],"stress","affect","endothelial function","2025-09-11",{"date":254,"type":38},"2025-09-17",{"date":256,"type":38},"2025-01-06",{"date":258,"type":22},"2031-12-01",{"name":44,"class":45},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":46},"100598406","examining-the-feasibility-of-implementing-a-hypertension-storytelling-intervention-among-african-americans-100598406","NCT07071077","Examining the Feasibility of Implementing a Hypertension Storytelling Intervention Among African Americans","Examining the Feasibility of Implementing a Hypertension Storytelling Intervention Among African Americans With Hypertension","Inclusion Criteria:\n\n* African American\u002FBlack\n* Diagnosed with Hypertension\n* Prescribed medication for hypertension\n\nExclusion Criteria:\n\n* Cognitive limitations that limit the ability to provide informed consent\n* Pregnancy\n* Unable to speak or read English\n* Planning to relocate during the study period",{"count":219,"type":22},[60],"The purpose of this study is to assess if storytelling is an effective approach for promoting lifestyle and behavioral change among individuals managing hypertension and to determine if storytelling interventions can help to reduce blood pressure and improve medication adherence.",[271],"Hypertension",[273,274,275],"Medication Adherence","Lifestyle Intervention","Behavioral Change","2025-07-16",{"date":278,"type":38},"2025-07-17",{"date":280,"type":38},"2025-01-29",{"date":210,"type":22},{"name":44,"class":45},{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":23,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":46},"100551353","disclosure-intervention-for-people-in-treatment-for-opioid-use-disorder-100551353","NCT06458985","Disclosure Intervention for People in Treatment for Opioid Use Disorder","Disclosure Intervention to Reduce Social Isolation and Facilitate Recovery Among People in Treatment for Opioid Use Disorder","Inclusion Criteria:\n\n* Client of Brandywine Counseling \\& Community Services\n* Receiving opioid use disorder treatment at Brandywine Counseling \\& Community Services\n* Considering disclosing one's opioid use disorder history and\u002For treatment to someone new\n\nExclusion Criteria:\n\n* Diagnosis of schizophrenia\n* Participation in pilot study of intervention",{"count":291,"type":22},480,[60],"The goal of this clinical trial is to test a disclosure intervention among people in treatment for opioid use disorder. The main question it aims to answer is whether people who receive a disclosure intervention have better treatment- and recovery-related outcomes one year after receiving the intervention. Participants will complete a brief disclosure intervention designed to help them (1) make key disclosures related to disclosure and (2) build skills to disclose. Researchers will compare results to participants in a waitlist comparator condition, who receive the intervention at the end of the study.",[295],"Opioid Use Disorder",[297,298,299,300],"disclosure","social isolation","stigma","social support","2025-07-15",{"date":303,"type":38},"2025-07-18",{"date":305,"type":38},"2024-05-20",{"date":307,"type":22},"2028-08-31",{"name":44,"class":45},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":16,"sex":55,"minAge":316,"maxAge":18,"enrollmentInfo":317,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":333,"leadSponsor":335,"locationsCount":46},"100591820","vascular-function-and-oxidative-stress-in-emergency-medical-responders-100591820","NCT06985394","Vascular Function and Oxidative Stress in Emergency Medical Responders","VF-EMT","Inclusion Criteria:\n\n* Body mass index between 18.5 and \\\u003C35 kg\u002Fm²\n* Seated resting systolic blood pressure \\\u003C 140 mmHg, and seated resting diastolic blood pressure \\\u003C 90 mmHg\n* Participant must be an active first responder that works shift work schedules. e.g., emergency medical responders, basic life support emergency medical technicians (i.e., BLS EMT), advanced life support emergency medical technicians (A-EMT), and paramedics\n* Participant must have been working shift work for at least 1 year\n* Participant must work at least 4 night shifts per month\n\nExclusion Criteria:\n\n* Participant is unwilling or unable to give consent\n* Participant has been diagnosed with any chronic disease (a history of high blood pressure, heart disease, diabetes, cancer, kidney disease)\n* Participant has been diagnosed with a sleep disorder (e.g., insomnia, restless leg syndrome, sleep apnea)\n* Participant is currently taking melatonin or other sleep aids (e.g., Ambien, sedatives, etc.), or any supplements\u002Fmedications known to alter sleep patterns. Participants using melatonin must undergo a minimum 72-hour washout period prior to study participation to ensure baseline sleep patterns are not affected\\[15, 16\\]\n* Resting blood pressure \\>140\u002F90 mmHg\n* Body mass index \\\u003C18.5 or \\>35 kg\u002Fm2\n* Currently pregnant or breast feeding (women only)\n* Currently use tobacco or nicotine products (≥1 cigarette, cigar, e-cigarette, vape, or any other nicotine-containing product in the last month), including smokeless tobacco (e.g., chewing tobacco, snuff, dip, snus), nicotine lozenges or gum, heated tobacco products, and any illicit drugs","20 Years",{"count":318,"type":22},45,[60],"The goal of this clinical trial is to characterize blood vessel function and oxidative stress (a harmful condition that damages cells and tissues) in emergency medical technicians (EMTs). The main questions it aims to answer are:\n\n1. Does an overnight shift work in emergency medical technicians reduce blood vessel function and increase oxidative stress?\n2. Can supplementing with antioxidants help reduce the negative effects of night shift work in emergency medical technicians?\n\nResearchers will compare antioxidants to a placebo (a look-alike substance that contains no drug) to see if antioxidants work in reducing the negative effects of night shift work in emergency medical technicians.\n\nParticipants will:\n\n1\\. Report to the lab two separate times following an overnight shift to assess blood vessel functioning and oxidative stress 3. Take an antioxidant supplement or placebo during each night of shift work.",[322],"Cardiovascular Function in EMTs",[324,325,326,327,328],"EMT","First Responder","Oxidative Stress","Paramedic","Emergency Medical Technician","2025-05-14",{"date":331,"type":38},"2025-05-22",{"date":329,"type":38},{"date":334,"type":22},"2025-10",{"name":44,"class":45},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":16,"sex":55,"minAge":343,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":350,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":46},"100557562","validation-of-texture-changing-coatings-for-use-in-at-home-rapid-tests-100557562","NCT06539728","Validation of Texture Changing Coatings for Use in At-Home Rapid Tests","Validation of Texture-Changing Tactile Coatings for Potential Use in Accessible At-Home Care","Inclusion Criteria:\n\n* Visual Impairment: Participants should be blind or visually impaired for greater than 10 years, either congenitally or acquired.\n* Tactile Aid Usage: Participants must use tactile aids regularly.\n* Mathematical Knowledge: Participants should have a basic understanding of mathematical plots, equivalent to at least high school geometry.\n\nExclusion Criteria:\n\n* Limb Conditions: Participants with amputations or outer extremity conditions affecting hand use will be excluded.","12 Years",{"count":5,"type":22},[60],"At-home testing is an important part of mitigating the spread of COVID-19, but these tests are not accessible to people with low vision or blindness. Instead of adapting to a technology originally built for sighted people, investigators propose a no-power version that reports test results through a texture change, which people can feel by touch. This platform could be used not only for COVID, but also for other diagnostics, and will promote the independence and privacy for people with low vision or blindness by removing the need for human assistance or an internet connection.",[348,349],"Vision, Low","Blindness",[351],"Tactile Aid","2025-04-03",{"date":354,"type":38},"2025-04-06",{"date":356,"type":22},"2025-06",{"date":358,"type":22},"2025-08",{"name":44,"class":45},{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":55,"minAge":366,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":46},"100586506","light-therapy-intervention-in-individuals-with-parkinsons-disease-100586506","NCT06916260","Light Therapy Intervention in Individuals With Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of Parkinson disease\n\nExclusion Criteria:\n\n1. Participants who are unable to comply with study visit\u002Ftesting requirements (e.g.\n\n   participants who cannot go off PD medication for the pre-, post-, and 3-month assessments).\n2. Participants who are unable to provide consent.\n3. Participants with a Deep Brain Stimulation (DBS) device.\n4. Participants who have a history of a psychiatric disorder\n5. Participants with PD who have other concurrent movement\u002Fneurological conditions, including dystonia, dementia, epilepsy etc.\n6. Participants with a clinical diagnosis of PD that is not considered primary (e.g.\n\n   vascular parkinsonism) or participants where an atypical form of parkinsonism is suspected (e.g., progressive supranuclear palsy, multiple system atrophy).\n7. Participants with a history of cancer (whether treated with chemotherapy and\u002For radiotherapy or not).\n8. Participants with a history of a recent concussion or any facial, neck, or head injury within the last 6 months. UD IRB Approved: 03\u002F12\u002F2025 IRBNet ID#: 2277769-2 I\u002FC from Rev. 01\u002F2024 Page 3 of 10 Participant's Initial's \\_\\_\\_\\_\\_\\_\\_\\_\n9. Known injury or disease that might interfere with motor function in the proposed experiments (e.g., stroke, traumatic brain injury, extrapyramidal dysfunction, neuromuscular disease, orthopedic problems that impair movement).\n10. Participants with a history of photosensitivity.\n11. Participants who are not able to walk unassisted for 2 minutes","50 Years","80 Years",{"count":5,"type":22},[60],"The study looks to investigate the effects that light therapy delivered to the frontal cortex could have on Parkinson's disease related symptoms ( both cognitive and motor). The therapy is a non invasive technique that deliverers low level wavelength light to the front part of the head for 12 minutes. for this study the therapy will be done 3 times a week for 6 weeks. To measure the potential effects on the therapy in Parkinson symptoms, we will do a set of cognitive and motor test before and after the intervention to measure any changes as well as control for any potential markers such as age, sex, disease level, medication and exercise.",[372],"Parkinson Disease","2025-03-31",{"date":375,"type":38},"2025-04-08",{"date":377,"type":22},"2025-04-04",{"date":379,"type":22},"2026-07-30",{"name":44,"class":45},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":16,"sex":55,"minAge":366,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":391,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":46},"100556735","western-diet-on-cardiometabolic-and-immune-function-100556735","NCT06528977","Western Diet on Cardiometabolic and Immune Function","Effects of a 10-day Western Diet on Cardiometabolic and Immune Function in Midlife Adults","WD","Inclusion Criteria:\n\n* ability to provide informed consent\n* men and postmenopausal women aged 50-64 years\n* systolic blood pressure \\\u003C 130 mmHg; diastolic blood pressure \\\u003C 90 mmHg\n* body mass index (BMI) \\\u003C30 kg\u002Fm2 and % body fat \\\u003C 25% for men and \\\u003C 33% for women\n* fasting triglycerides \\\u003C 200 mg\u002Fdl (\\\u003C 2.3 mmol\u002FL)\n* low density lipoprotein (LDL) cholesterol \\\u003C160 mg\u002Fdl (4.14 mmol\u002FL)\n* fasting plasma glucose \\\u003C126 mg\u002Fdl (\\\u003C7.0 mmol\u002FL)\n* weight stable in the prior 6 months (≤ 2 kg weight change)\n* blood chemistries indicative of normal liver enzymes and renal function (estimated glomerular filtration rate using the Modification of Diet in Renal Disease (MDRD) prediction equation must be \\>60 ml\u002Fmin\u002F1.73 m\\^2)\n\nExclusion Criteria:\n\n* current use of medications or supplements known to lower blood triglycerides or cholesterol (e.g., fibrates, statins, high dose niacin, high dose omega-3 supplement)\n* chronic clinical diseases (e.g., coronary artery\u002Fperipheral artery\u002Fcerebrovascular diseases, heart failure, diabetes, chronic kidney disease requiring dialysis, neurological or autoimmune conditions affecting cognition (e.g. Alzheimer's disease or other forms of dementia, Parkinson's disease, epilepsy, multiple sclerosis, large vessel infarct)\n* major psychiatric disorder (e.g. schizophrenia, bipolar disorder)\n* current or past (i.e., last 3 months) use of anti-hypertensive or other cardiovascular-acting medications known to influence vascular function and\u002For arterial stiffness\n* current medication use likely to affect central nervous system (CNS) functions (e.g. long active benzodiazepines)\n* concussion within last 2 years and ≥ 3 lifetime concussions\n* heavy alcohol consumption (≥8 drinks\u002Fweek for women and ≥15 drinks\u002Fweek for men)\n* recent major change in health status within the previous 6 months (i.e., surgery, significant infection, or illness)\n* current smoking within the past 3 months.","64 Years",{"count":5,"type":22},[60],"This study will implement a Western Diet (WD) to understand cardiometabolic and immune function in middle-aged adults (50- 64 years old). Vascular health, intestinal permeability, and T-cell function will be examined before, during, and after the WD. The WD is a 10-day diet and will consist of 25% of total energy from added sugars.",[200,394],"Diet, Healthy",[396,397,398,399,400],"added sugars","western diet","cardiometabolic health","T-cell function","intestinal permeability","2024-07-29",{"date":403,"type":38},"2024-07-30",{"date":405,"type":38},"2024-07-17",{"date":407,"type":22},"2027-07",{"name":44,"class":45},{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":55,"minAge":416,"maxAge":417,"enrollmentInfo":418,"targetDuration":420,"studyType":421,"phases":4,"briefSummary":422,"conditions":423,"keywords":424,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":46},"100400648","university-of-delaware-parkinsons-disease-registry-100400648","NCT04496973","University of Delaware Parkinson's Disease Registry","University of Delaware Participant Recruitment Registry for Parkinson's Disease Research","Inclusion Criteria:\n\n* Individual 21 years old or older\n* A clinical diagnosis of Parkinson's disease\n* Interest in participating in one or more investigator-led research studies at the University of Delaware\n\nExclusion Criteria:\n\n* Individuals with a clinical diagnosis of parkinsonism that is not considered primary (e.g. vascular parkinsonism) or an atypical parkinsonian syndrome (e.g., progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration etc.)\n* Clinical diagnosis of dementia","21 Years","100 Years",{"count":419,"type":22},1000,"1 Year","OBSERVATIONAL","The purpose of this Parkinson's Disease Registry is to assist with recruitment of willing participants into future Parkinson's disease research studies at the University of Delaware.",[372],[425],"Parkinson's Disease","2024-05-13",{"date":428,"type":38},"2024-05-16",{"date":430,"type":38},"2020-05-28",{"date":432,"type":22},"2030-01-01",{"name":44,"class":45},{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":16,"sex":55,"minAge":440,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":444,"conditions":445,"keywords":446,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":46},"100534361","testing-tactile-aids-with-blind-subjects-100534361","NCT06237829","Testing Tactile Aids With Blind Subjects","Inclusion Criteria:\n\n* Visual Impairment: Participants should be blind or visually impaired for greater than 10 years, either congenitally or acquired.\n* Tactile Aid Usage: Participants must use tactile aids regularly.\n* Mathematical Knowledge: Participants should have a basic understanding of mathematical plots, equivalent to at least high school geometry.\n\nExclusion Criteria:\n\n\\- Limb Conditions: Participants with amputations or outer extremity conditions affecting hand use will be excluded.","16 Years",{"count":442,"type":22},100,[60],"The objective of this project is to create richer tactile aids by using materials chemistry to create tactile sensations in tactile aids, as an alternative to traditional physical bumps, lines, or textures. These materials are commonly used in household products, but have not yet been used to enrich tactile aids. Successful outcomes are primarily the accuracy with which low vision or blind subjects identify objects made from tactile coatings versus traditional tactile aids. Other outcomes include time to completion of the task, or the number of distinctive categories that participants can identify.",[348,349],[351],"2024-03-11",{"date":449,"type":38},"2024-03-13",{"date":451,"type":38},"2021-09-01",{"date":453,"type":22},"2027-12",{"name":44,"class":45},{"id":456,"slug":457,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":16,"sex":55,"minAge":56,"maxAge":367,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":472,"locationsCount":46},"100516762","model-informed-patient-specific-rehabilitation-using-robotics-and-neuromuscular-modeling-100516762","NCT06008743","Model-informed Patient-specific Rehabilitation Using Robotics and Neuromuscular Modeling","Inclusion Criteria:\n\nTwo groups of subjects will be included in the study.\n\nGroup A: Individuals must be between the ages of 18 and 80 years, be in general good health, and be proficient in English. The subjects' physical fitness for participation in the research procedures will be documented via the Physical Readiness Questionnaire (PAR-Q). Their answers to the PAR-Q will be evaluated by the study team to determine if they are suitable for the study. Individuals should not have significant musculoskeletal conditions (osteoarthritis, joint replacement etc). The subjects' resting heart rate must be between 60-100 beats per minute, while their resting blood pressure between 90\u002F60 to 140\u002F90. The subjects should weigh under 250 pounds (lbs).\n\nGroup B: Individuals must be between the ages of 18 and 80 years, speak English, have a single, unilateral, chronic stroke (\\>6 months post-stroke), confirmed by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) scan. They should be able to walk at a self-selected speed for at least 15 minutes without assistance from another person. They should be able to respond to questions during screening, provide informed consent and fully follow instructions. The subjects' resting heart rate must be between 60-100 beats per minute, while their resting blood pressure between 90\u002F60 to 160\u002F90. The subjects should weigh under 250 pounds (lbs).\n\nExclusion Criteria:\n\n* Any neurological conditions (applicable to Group A - healthy subjects) or other neurological conditions in addition to stroke (applicable to Group B - stroke survivors);\n* Inability to walk outside the home before the stroke (applicable to Group B - stroke survivors);\n* Coronary artery bypass graft in the past 3 months, myocardial infarction in the past 3 months, uncontrolled or untreated atrial fibrillation, severe or painful peripheral vascular disease, diagnosis of heart failure, or unstable or untreated angina;\n* Expressive aphasia\n* Reported musculoskeletal pain or conditions that limit walking (such as tendonitis, arthritis, osteoporosis, spinal stenosis, or any orthopedic surgery or fracture to the legs or spine in the last 6 months);\n* Inability to communicate with investigators (e.g., due to severe aphasia or other cognitive impairment);\n* Severe respiratory problems such as chronic obstructive pulmonary disease (COPD);\n* Unexplained dizziness;\n* Weight greater than 250 pounds (lbs).\n* Inability to ascend and descend 4 steps with handrails using another person's assistance (if desired)",{"count":462,"type":22},72,[60],"Stroke is the third leading cause of death and the primary cause of long-term disability in the United States, affecting approximately 795,000 people each year. Hemiparesis, or unilateral weakness, is common after stroke and responsible for changes in muscle activation and movement patterns as well as declines in walking speed. It has been shown that increased walking speed directly corresponds to a higher quality of life in older adults and therefore, is often the goal of motor rehabilitation after stroke. However, there is no consensus on the best method for improving walking function after stroke and the results of post-stroke gait studies vary widely across sites and studies. Walking is one of the human's most important functions that serve survival, progress, and interaction. The force between the foot and the walking surface is very important. Although there have been many studies trying to understand this, there is a need for the development of a system that can advance research and provide new functionality. In this work, we will conduct a series of studies that attempt to analyze human gait and adaptations from different perspectives.",[87],"2023-08-20",{"date":468,"type":38},"2023-08-24",{"date":470,"type":38},"2022-09-21",{"date":234,"type":22},{"name":44,"class":45},{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":16,"sex":55,"minAge":56,"maxAge":81,"enrollmentInfo":479,"targetDuration":4,"studyType":23,"phases":480,"briefSummary":481,"conditions":482,"keywords":484,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":46},"100409824","online-motor-control-in-people-with-parkinsons-disease-100409824","NCT04616508","Online Motor Control in People With Parkinson's Disease","Inclusion criteria (all participants):\n\n* Age 18-85 years\n* Able to perform reaching movements of \\~20 cm (8 inches)\n* MMSE score ≥ 26\u002F30\n* Willing and able to attend all testing sessions\n\nInclusion criteria (PD group only):\n\n* Diagnosis of idiopathic Parkinson's disease per self report\n* Currently taking dopaminergic\u002Fdopamine agonist medication\n\nExclusion criteria (all participants):\n\n* Any chronic or recent upper extremity musculoskeletal conditions that affects reaching\n* Any neurological disorders other than Parkinson's disease (e.g., seizure disorders, closed head injuries with loss of consciousness greater than 15 minutes, CNS neoplasm, history of stroke)",{"count":442,"type":22},[60],"This study aims to better understand how people with Parkinson's control reaching movements. Specifically, we are asking how these individuals respond to different environmental perturbations. Testing includes reaching movements made within a virtual reality set-up.",[483,372],"Motor Control",[485,486,487],"motor control","Parkinson disease","motor learning","2020-10-30",{"date":490,"type":38},"2020-11-05",{"date":492,"type":38},"2018-12-12",{"date":494,"type":22},"2026-12-12",{"name":44,"class":45},""]